Andrea Sturchio
@andrea_sturchio
MD, Neurologist, Ph.D. student - Karolinska Institutet - Department of Clinical Neuroscience Founder of RegainTherapeutics @RegainNeuro
New research from @PerSvenningsson & colleagues provides further support for cerebrospinal fluid DOPA decarboxylase levels as an emerging biomarker for #Parkinsons; Correlates with⬇️DaT-SPECT binding in data from the Biopark & PPMI cohorts (n=51+72, resp) …mentdisorders.onlinelibrary.wiley.com/doi/10.1002/md…
Smart insulin switches itself off in response to low blood sugar nature.com/articles/d4158…
FDA approves a novel drug for schizophrenia. The effects of xanomeline are mediated through M₁ and M₄ muscarinic receptors with no direct D₂ dopamine receptor-blocking activity. washingtonpost.com/business/2024/…
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine–associated receptor 1 | Science Advances science.org/doi/10.1126/sc…
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease | Translational Neurodegeneration | Full Text …alneurodegeneration.biomedcentral.com/articles/10.11…
Increased CSF DOPA Decarboxylase Correlates with Lower DaT‐SPECT Binding: Analyses in Biopark and PPMI Cohorts - Khosousi & Sturchio et al. - Movement Disorders - Wiley Online Library …mentdisorders.onlinelibrary.wiley.com/doi/10.1002/md…
One of my favorite scientists agrees with what we claimed in our papers …. @Kariem_Ezzat @AlbertoEspay pubmed.ncbi.nlm.nih.gov/34505023/ pubmed.ncbi.nlm.nih.gov/36120786/ pubmed.ncbi.nlm.nih.gov/35453734/
Did you catch Nobel Prize winner Thomas Sudhof’s presentation?💡 “One plausible hypothesis is that Aß plaques are Aß sinks that lower the free Aß concentration, and that it is the loss of free Aß instead of an Aß toxicity that promotes AD pathogenesis” #ADPD2024
Another important study showed that lower CSF AB42 levels is the first biomarker alteration in Alzheimer's disease. Another important point: the ratio between AB42 and AB40 decreases as well over time. nejm.org/doi/pdf/10.105…
Another failure for monoclonal antibody against alpha-synuclein (cinpanemab). The study enrolled early PD subjects. neurology.org/doi/10.1212/WN…
Biogen will terminate the Phase 4 trial for Aducanumab. "I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved" science.org/content/blog-p…
